Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD and food effect study of HEC122505 in healthy volunteers
NCT04625361Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEC122505 in Parkinson's disease (PD) (10 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Number of Adverse Events. Started Jan 2021; status: completed.
02
Drugs
HEC122505
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04625361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625361.